Emerging Markets Series: The Pharmaceutical Market of Poland
Table of Contents
Overview 1
ABOUT DATAMONITOR HEALTHCARE 2
About the Strategic Pharmaceutical Analysis Team 2
Chapter 1 - Executive Summary 3
Scope 3
Key findings 3
Related reports 3
Table of Contents 4
Chapter 2 - Demographic trends in Poland 5
Key findings 5
Socio and business demographics of Poland 6
Poland is politically stable 7
The introduction of Special Economic Zones offer a major incentive for foreign investment 7
Major incentives to investing in Poland 8
Major disincentives to investing in Poland 9
Low corporation income tax is an incentive for foreign investment in Poland 10
Polish international trade largely confined to the EU 10
Poland invests little in research and development 11
Pharmaceutical research and development in Poland is set to increase 12
Chapter 3 - The healthcare system in Poland 14
Key findings 14
The healthcare system in Poland 15
Healthcare expenditure in Poland 16
Polish healthcare system is in need of reform 17
Hospital debt and corruption are crippling the public healthcare system 17
Polish regulatory landscape 18
Polish pharmaceutical industry legislation 20
Pricing and Reimbursement system in Poland lacks consistency 21
Pricing controls in Poland 21
Reference pricing in Poland 21
Hospital tendering procedures 22
Reimbursement controls in Poland 22
Positive formulary lists 23
Agency for Health Technology Assessment (AHTAPol) introduced to curb spending 24
Pharmacy substitution is a recent change implemented by the Polish government to offer patients greater choice 25
Chapter 4 - Polish pharmaceutical market 26
Key findings 26
Polish pharmaceutical market is growing rapidly 27
Polish retail market is growing rapidly in value 28
Cardiovascular, CNS and respiratory pharmaceuticals dominate the Polish retail market 29
Top brands in the Polish retail market 31
Poland's hospital pharmaceutical market is growing steadily 32
Top brands in Poland's hospital market 32
Oncology drug sales dominate Poland's hospital market 33
Top pharmaceutical players in Poland are all international companies 34
Novartis - Poland 35
GlaxoSmithKline - Poland 36
Generic players dominate Poland's pharmaceutical market 37
Polpharma's - Poland's domestic giant 38
Polish patent and intellectual property law in desperate need of reform 38
Chapter 5 - Bibliography 40
APPENDIX 45
Exchange rates 45
About Datamonitor 46
About Datamonitor Healthcare 46
Datamonitor consulting 46
Disclaimer 48
List of Tables
Table 1: Poland: health demographics, 2002-06 6
Table 2: Poland:, World Health Organization (WHO) core health indicators for healthcare expenditure, 2005 16
Table 3: Poland: sales for the top ATC groups in the retail pharmaceutical market, 2005-08 30
Table 4: Poland: top 12 brands in the retail pharmaceutical market, 2005-2008 31
Table 5: Poland: top 12 brands in the hospital pharmaceutical market, 2005-2008 32
Table 6: Poland: sales for the top ATC groups in hospital pharmaceutical market, 2005-08 34
Table 7: Poland: top 10 drug manufacturing companies, 2007-08 35
Table 8: Poland: top 10 generic pharmaceutical companies, 2008 37
Table 9: Exchange rates, 2008 45
List of Figures
Figure 1: Drivers and resistors to investing in Poland 10
Figure 2: Poland: scientific and innovative indicators, 2009 11
Figure 3: SWOT analysis of the Polish biotechnology market, 2008 12
Figure 4: Poland: population estimates, 1980-2050 15
Figure 5: Poland: value of private healthcare market (PLN billion), 2005-10 18
Figure 6: Poland: healthcare system network, 2009 19
Figure 7: Poland: combined total drug sales, 2005-08 27
Figure 8: Poland: value and volume sales for the retail pharmaceutical market, 2005-08 28
Figure 9: Poland: top ATC groups in the retail pharmaceutical market, 2005-07 30 Figure 10: Poland: sales for the top ATC groups in the hospital pharmaceutical market,
2007 33